Claudine Soria

Title: Claudine Soria: Innovator in Angiogenesis Research

Introduction

Claudine Soria is a prominent inventor based in Taverny, France. She has made significant contributions to the field of angiogenesis research, with a focus on developing methods to inhibit tumor growth and metastasis. With a total of three patents to her name, Soria's work has the potential to impact cancer treatment significantly.

Latest Patents

One of her latest patents is a method of inhibiting angiogenesis or invasion or formation of metastases in mammals. This method involves administering a therapeutically effective amount of an active agent, which can include a protein substance or a nucleic acid molecule that targets the disintegrin domain of an adamalysin. Another notable patent is related to adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for tumor treatment. This invention focuses on gene therapy, specifically the introduction of a gene encoding an anti-angiogenic factor into tumor cells using a defective adenovirus vector. The results have shown promising inhibition of tumor growth and metastasis, along with a significant reduction in neovascularization at the injection site.

Career Highlights

Claudine Soria has worked with esteemed organizations such as the Institut des Vaisseaux et du Sang and the Centre National de la Recherche Scientifique. Her research has been pivotal in advancing the understanding of angiogenesis and its role in cancer progression.

Collaborations

Throughout her career, Soria has collaborated with notable colleagues, including He Lu and Pierre Jolles. These partnerships have contributed to her innovative research and the development of her patents.

Conclusion

Claudine Soria's work in angiogenesis research exemplifies the impact of innovative thinking in the medical field. Her patents reflect a commitment to advancing cancer treatment through scientific discovery.